Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Prince

Showing results (161-170 of 168) with videos related to

Pageof 17
Sort By:
You have reached the last page of results.This site can display upto 168 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 12, 2015
Outcomes of Nonmyeloablative HLA-Haploidentical Blood or Marrow Transplantation With High-Dose Post-Transplantation Cyclophosphamide in Older AdultsYvette L Kasamon, Javier Bolaños-Meade, Gabrielle T Prince, et al.
Haematologica|May 8, 2025
Improved outcomes of acute lymphoblastic leukemia after allogeneic blood or marrow transplantation with high-dose post-transplantation cyclophosphamide in the era of more effective pre-transplant therapyJonathan A Webster, Madison Reed, Hua-Ling Tsai, et al.
Blood|March 28, 2015
Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamideShannon R McCurdy, Jennifer A Kanakry, Margaret M Showel, et al.
Transplantation and Cellular Therapy|January 1, 2023
Allogeneic Blood or Marrow Transplantation with High-Dose Post-Transplantation Cyclophosphamide for Acute Lymphoblastic Leukemia in Patients Age ≥55 YearsJonathan A Webster, Madison Reed, Hua-Ling Tsai, et al.
Blood|December 17, 2019
Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemiaGail J Roboz, Courtney D DiNardo, Eytan M Stein, et al.
The New England Journal of Medicine|June 5, 2018
Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AMLCourtney D DiNardo, Eytan M Stein, Stéphane de Botton, et al.
The Journal of Allergy and Clinical Immunology|October 13, 2022
Monogenic early-onset lymphoproliferation and autoimmunity: Natural history of STAT3 gain-of-function syndromeJennifer W Leiding, Tiphanie P Vogel, Valentine G J Santarlas, et al.
Journal of Clinical Immunology|April 5, 2024
COVID-19 Vaccination in Patients with Inborn Errors of Immunity Reduces Hospitalization and Critical Care Needs Related to COVID-19: a USIDNET ReportJohn McDonnell, Kimberley Cousins, M Elizabeth M Younger, et al.
Pageof 17

Showing results (161-170 of 168) with videos related to

Sort By:
Pageof 17
You have reached the last page of results.This site can display upto 168 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 12, 2015
Outcomes of Nonmyeloablative HLA-Haploidentical Blood or Marrow Transplantation With High-Dose Post-Transplantation Cyclophosphamide in Older AdultsYvette L Kasamon, Javier Bolaños-Meade, Gabrielle T Prince, et al.
Haematologica|May 8, 2025
Improved outcomes of acute lymphoblastic leukemia after allogeneic blood or marrow transplantation with high-dose post-transplantation cyclophosphamide in the era of more effective pre-transplant therapyJonathan A Webster, Madison Reed, Hua-Ling Tsai, et al.
Blood|March 28, 2015
Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamideShannon R McCurdy, Jennifer A Kanakry, Margaret M Showel, et al.
Transplantation and Cellular Therapy|January 1, 2023
Allogeneic Blood or Marrow Transplantation with High-Dose Post-Transplantation Cyclophosphamide for Acute Lymphoblastic Leukemia in Patients Age ≥55 YearsJonathan A Webster, Madison Reed, Hua-Ling Tsai, et al.
Blood|December 17, 2019
Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemiaGail J Roboz, Courtney D DiNardo, Eytan M Stein, et al.
The New England Journal of Medicine|June 5, 2018
Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AMLCourtney D DiNardo, Eytan M Stein, Stéphane de Botton, et al.
The Journal of Allergy and Clinical Immunology|October 13, 2022
Monogenic early-onset lymphoproliferation and autoimmunity: Natural history of STAT3 gain-of-function syndromeJennifer W Leiding, Tiphanie P Vogel, Valentine G J Santarlas, et al.
Journal of Clinical Immunology|April 5, 2024
COVID-19 Vaccination in Patients with Inborn Errors of Immunity Reduces Hospitalization and Critical Care Needs Related to COVID-19: a USIDNET ReportJohn McDonnell, Kimberley Cousins, M Elizabeth M Younger, et al.
Pageof 17